Urinary excretion of Bowman-Birk inhibitor in humans after soy consumption as determined by a monoclonal antibody-based immunoassay

X. Steven Wan, Leejane Lu, Karl Anderson, Jeffrey H. Ware, Ann R. Kennedy

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The Bowman-Birk inhibitor (BBI) found in soybeans is a serine protease inhibitor with anticarcinogenic activity. In the present study, an ELISA for BBI was developed with the use of a monoclonal antibody against a reduced form of BBI. This newly developed ELISA method was used to measure the urinary levels of BBI metabolites in nine human subjects after consumption of 36-oz or 60-oz soymilk (containing 105 or 175 mg of BBI) at two time points 36 h apart. The results demonstrate that urinary BBI excretion rates peaked within 6 h and decreased to baseline levels within 12-24 h after soymilk ingestion. The changes in BBI:creatinine ratios in urine closely paralleled the changes in urinary BBI excretion rates after soymilk consumption. These data suggest that BBI ingested p.o. is absorbed and could be bioavailable for cancer chemoprevention in other organs in addition to those in the gastrointestinal tract.

Original languageEnglish
Pages (from-to)741-747
Number of pages7
JournalCancer Epidemiology Biomarkers and Prevention
Volume9
Issue number7
StatePublished - Jul 2000

Fingerprint

Immunoassay
Enzyme-Linked Immunosorbent Assay
Monoclonal Antibodies
Serine Proteinase Inhibitors
Chemoprevention
Soybeans
Gastrointestinal Tract
Creatinine
Eating
Urine
Neoplasms

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Urinary excretion of Bowman-Birk inhibitor in humans after soy consumption as determined by a monoclonal antibody-based immunoassay. / Wan, X. Steven; Lu, Leejane; Anderson, Karl; Ware, Jeffrey H.; Kennedy, Ann R.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 9, No. 7, 07.2000, p. 741-747.

Research output: Contribution to journalArticle

@article{ae06fd14f6854dedae6107f5d1225aed,
title = "Urinary excretion of Bowman-Birk inhibitor in humans after soy consumption as determined by a monoclonal antibody-based immunoassay",
abstract = "The Bowman-Birk inhibitor (BBI) found in soybeans is a serine protease inhibitor with anticarcinogenic activity. In the present study, an ELISA for BBI was developed with the use of a monoclonal antibody against a reduced form of BBI. This newly developed ELISA method was used to measure the urinary levels of BBI metabolites in nine human subjects after consumption of 36-oz or 60-oz soymilk (containing 105 or 175 mg of BBI) at two time points 36 h apart. The results demonstrate that urinary BBI excretion rates peaked within 6 h and decreased to baseline levels within 12-24 h after soymilk ingestion. The changes in BBI:creatinine ratios in urine closely paralleled the changes in urinary BBI excretion rates after soymilk consumption. These data suggest that BBI ingested p.o. is absorbed and could be bioavailable for cancer chemoprevention in other organs in addition to those in the gastrointestinal tract.",
author = "Wan, {X. Steven} and Leejane Lu and Karl Anderson and Ware, {Jeffrey H.} and Kennedy, {Ann R.}",
year = "2000",
month = "7",
language = "English",
volume = "9",
pages = "741--747",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Urinary excretion of Bowman-Birk inhibitor in humans after soy consumption as determined by a monoclonal antibody-based immunoassay

AU - Wan, X. Steven

AU - Lu, Leejane

AU - Anderson, Karl

AU - Ware, Jeffrey H.

AU - Kennedy, Ann R.

PY - 2000/7

Y1 - 2000/7

N2 - The Bowman-Birk inhibitor (BBI) found in soybeans is a serine protease inhibitor with anticarcinogenic activity. In the present study, an ELISA for BBI was developed with the use of a monoclonal antibody against a reduced form of BBI. This newly developed ELISA method was used to measure the urinary levels of BBI metabolites in nine human subjects after consumption of 36-oz or 60-oz soymilk (containing 105 or 175 mg of BBI) at two time points 36 h apart. The results demonstrate that urinary BBI excretion rates peaked within 6 h and decreased to baseline levels within 12-24 h after soymilk ingestion. The changes in BBI:creatinine ratios in urine closely paralleled the changes in urinary BBI excretion rates after soymilk consumption. These data suggest that BBI ingested p.o. is absorbed and could be bioavailable for cancer chemoprevention in other organs in addition to those in the gastrointestinal tract.

AB - The Bowman-Birk inhibitor (BBI) found in soybeans is a serine protease inhibitor with anticarcinogenic activity. In the present study, an ELISA for BBI was developed with the use of a monoclonal antibody against a reduced form of BBI. This newly developed ELISA method was used to measure the urinary levels of BBI metabolites in nine human subjects after consumption of 36-oz or 60-oz soymilk (containing 105 or 175 mg of BBI) at two time points 36 h apart. The results demonstrate that urinary BBI excretion rates peaked within 6 h and decreased to baseline levels within 12-24 h after soymilk ingestion. The changes in BBI:creatinine ratios in urine closely paralleled the changes in urinary BBI excretion rates after soymilk consumption. These data suggest that BBI ingested p.o. is absorbed and could be bioavailable for cancer chemoprevention in other organs in addition to those in the gastrointestinal tract.

UR - http://www.scopus.com/inward/record.url?scp=0033942129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033942129&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 741

EP - 747

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 7

ER -